Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pembrolizumab and EDP1503 in Advanced Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma (Skin)
Melanoma

Interventions: Drug: Pembrolizumab
Biological: EDP1503

First Posted Date: 2018-07-23

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 8

Registration Number: NCT03595683

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

An Early Real-Time Electronic Health Record Risk Algorithm for the Prevention and Treatment of Acute Kidney Injury

Not Applicable

Recruiting

Conditions: Acute Kidney Injury

Interventions: Other: Standard of Care (SOC)
Other: Early Nephrology Consult (ENC)

First Posted Date: 2018-07-18

Last Posted Date: 2024-08-06

Lead Sponsor: University of Chicago

Target Recruit Count: 180

Registration Number: NCT03590028

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy

Not Applicable

Recruiting

Conditions: Prostate Cancer

Interventions: Procedure: Diagnostic MRI
Procedure: Diagnostic Prostate Biopsy
Device: Risk Map DSS tool

First Posted Date: 2018-07-13

Last Posted Date: 2023-08-25

Lead Sponsor: University of Chicago

Target Recruit Count: 100

Registration Number: NCT03585660

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Phase 1

Terminated

Conditions: Endometrial Cancer
Prostate Cancer

Interventions: Drug: Rucaparib
Drug: Nivolumab

First Posted Date: 2018-06-28

Last Posted Date: 2021-03-09

Lead Sponsor: University of Chicago

Target Recruit Count: 12

Registration Number: NCT03572478

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: ALL, Childhood
ALL
Acute Lymphoblastic Leukemia

Interventions: Drug: Ruxolitinib
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Vincristine
Drug: Pegaspargase
Drug: Rituximab
Drug: Methotrexate (Intrathecal Administration)
Drug: Methotrexate (Intravenous Administration)
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Thioguanine
Drug: Methotrexate Oral Product

First Posted Date: 2018-06-27

Last Posted Date: 2024-12-20

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT03571321

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

An Emotion-Focused Intervention for Glycemic Control in T2D

Not Applicable

Completed

Conditions: Type2 Diabetes

Interventions: Behavioral: Emotion-Focused CBT

First Posted Date: 2018-06-12

Last Posted Date: 2020-04-22

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT03553680

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors

Phase 2

Completed

Conditions: Skin-Picking
Trichotillomania

Interventions: Drug: Placebo
Drug: Dronabinol

First Posted Date: 2018-05-21

Last Posted Date: 2022-06-02

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT03530800

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma
Myeloma

Interventions: Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-04-18

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 75

Registration Number: NCT03500445

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes

Not Applicable

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Other: Diabetes MESSAGES Program (second trial)
Other: Diabetes MESSAGES Program

First Posted Date: 2018-04-04

Last Posted Date: 2022-11-03

Lead Sponsor: University of Chicago

Target Recruit Count: 265

Registration Number: NCT03487692

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Effects of THC on Emotional Memory Retrieval

Early Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo oral capsule
Drug: THC

First Posted Date: 2018-03-20

Last Posted Date: 2019-05-30

Lead Sponsor: University of Chicago

Target Recruit Count: 24

Registration Number: NCT03471585

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy